PATENT CLAIM ANALYSIS

Application Number: 16045400
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-11
Patent Classification: ["530", "391900"]

Abstract:
The present invention relates to therapeutic conjugates with improved ability to target various diseased cells containing a targeting moiety (such as an antibody or antibody fragment), a linker and a therapeutic moiety, and further relates to processes for making and using the conjugates.

Claim (Index 20):
A method of delivering SN-38 to a cancer cell comprising administering to the cancer cell an immunoconjugate having a structural formula MAb-linker-SN-38, wherein the linker-SN-38 has a structure represented by: wherein n is between 1 and 30; AA is an L-amino acid residue selected from the group consisting of alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine; R is a thiol-reactive moiety; and MAb is an IgG antibody or antigen-binding antibody fragment that binds to the cancer cell.

Metadata:
- Claim Count in Document: 62.0
- Percentile: 95.0
- Lexical Diversity: 1.33333
- Patent Class: 530.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15587526', '15133675', '15267910', '14636790', '14294651']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7077328328268371
- 35 USC 102 Novelty (BERT): 0.600112156438842
- Combined Prediction Score: 0.6969707651880376
- Mean Citation Score: 482.2731
- Max Citation Score: 507.62848
- Similarity Product: 493.13815335105903

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test